BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9088081)

  • 21. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
    Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
    J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
    Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
    Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma.
    Watts MJ; Sullivan AM; Jamieson E; Pearce R; Fielding A; Devereux S; Goldstone AH; Linch DC
    J Clin Oncol; 1997 Feb; 15(2):535-46. PubMed ID: 9053475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Target value tailored (TVT) apheresis approach for blood progenitor cell collection after high-dose chemotherapy and rh-G-CSF.
    Mitterer M; Hirber J; Gentilini I; Prinoth O; Fabris P; Emmerich B; Coser P; Straka C
    Bone Marrow Transplant; 1996 Sep; 18(3):611-7. PubMed ID: 8879626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft.
    Dreger P; Haferlach T; Eckstein V; Jacobs S; Suttorp M; Löffler H; Müller-Ruchholtz W; Schmitz N
    Br J Haematol; 1994 Jul; 87(3):609-13. PubMed ID: 7527648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF.
    Delamain MT; Metze K; Marques JF; Reis AR; De Souza CA; Lorand-Metze I
    Transfus Apher Sci; 2006 Feb; 34(1):33-40. PubMed ID: 16376618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F; Cavenaghi L; de Melo CM
    Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization.
    Kozuka T; Ikeda K; Teshima T; Kojima K; Matsuo K; Bessho A; Sunami K; Hiramatsu Y; Maeda Y; Noguchi T; Yamamoto K; Fujii N; Imai T; Takenaka K; Shinagawa K; Ishimaru F; Niiya K; Koide N; Tanimoto M; Harada M
    Transfusion; 2002 Nov; 42(11):1514-22. PubMed ID: 12421227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients.
    Fruehauf S; Schmitt K; Veldwijk MR; Topaly J; Benner A; Zeller WJ; Ho AD; Haas R
    Br J Haematol; 1999 Jun; 105(3):786-94. PubMed ID: 10354148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients.
    Petit J; Boqué C; Cancelas JA; Sarrà J; Muñoz J; Garcia J; Grañena A
    Leuk Lymphoma; 1999 Jun; 34(1-2):119-27. PubMed ID: 10350339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC).
    Benet I; Prosper BF; Marugan I; Lluch A; Arbona C; Castillo I; Solano C; Garcia-Conde J
    Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections.
    Webb IJ; Eickhoff CE; Elias AD; Ayash LJ; Wheeler CA; Schwartz GN; Demetri GD; Anderson KC
    Transfusion; 1996 Feb; 36(2):160-7. PubMed ID: 8614968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.